Jafron Biomedical (SZ 300529) released the annual report on April 12th. A strong performance is recorded under the challenging circumstances of the COVID-19 pandemic, containing the summary of business operation, strategic priorities and financial statements implemented in 2021.

Jafron maintained its position in the industry with stable revenue growth and operational resilience. In 2021, the consolidated revenue ended at $421 million, with a year-to-year growth of 37.15%, generating a net profit of $188 million, an increase of 36.74% from 2020. In particular, the R&D expenses reached $27 million, with an escalation of 115.17%.

As a manufacturer of Class-III medical devices, Jafron obtained seven new product registration certificates in China in 2021 and has been awarded as a class-A medical device manufacturer of quality credit in Guangdong Province for ten consecutive years. The company has 20 medical device registration certificates and 270 authorized patents up to the present. Moreover, Jafron was awarded as one of the top enterprises in the list of Championship in the Individual Manufacturing Industry by the Chinese Ministry of Industry and Information Technology (MIIT) during the reporting period. It is worth mentioning that although affected by the COVID-19 pandemic, the international market has achieved rapid growth by adopting various innovative measures. As of the publication date of the annual report, Jafron's hemoperfusion products have been applied in more than 80 countries, in 11 of which medical insurances are effective. Meanwhile, the adsorption technology has been embedded into COVID-19 treatment guidelines & recommendations in 11 countries, including Morocco and the United Kingdom.

In the annual report, Jafron emphasized the priority of enlarging investment in production and scientific research and introducing more high-tech talents in the future. In particular, Jafron will expand the portfolios with the leverage of the research pipeline and market needs to generate an ecosystem in the industry. Furthermore, Jafron will particularly focus on the blood purification market, dedicated to researching purification therapies targeting inflammatory mediators, immunity, bilirubin, endotoxin, etc., expanding the market of new prospective segments such as severe liver disease, cardiac surgery, and critical illness. Last but not least, the rapid expansion of the international market is prioritized at the upstream level of company strategy.